Phuturdex › Diseases › Adenocarcinoma of the lung
Drugs in development · updated 30 October 2026
Adenocarcinoma of the lung: drugs in development
As of 30 October 2026 there are 41 active clinical trials (recruiting or ongoing, phases I–III) on 50 drugs for adenocarcinoma of the lung. 21 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| FurmonertinibFirmonertinib, Furmonertinib Mesilate Tablets | II | 4 | NCT07878871 |
| AlmonertinibAumolertinib, HS-10296 | II | 1 | NCT07624487 |
| AnlotinibAL3818, Anrotinib | II | 1 | NCT06483672 |
| ApatinibRivoceranib | II | 1 | NCT02493582 |
| BenmelstobartTQB2450 | II | 1 | NCT06528847 |
| Devimistat | II | 1 | NCT05733000 |
| LP-300 | II | 1 | NCT05456256 |
| Methoxyamine | II | 1 | NCT05198830 |
| PalacaparibAZD9574 | I–II | 1 | NCT05797168 |
| QL1706 | II | 1 | NCT07416058 |
| SaruparibAZD5305 | I–II | 1 | NCT05797168 |
| SL-28 | I–II | 1 | NCT07341737 |
| SpartalizumabPDR001 | II | 1 | NCT04802876 |
| TNG260 | I–II | 1 | NCT05887492 |
| Torvutatug samrotecan | I–II | 1 | NCT05797168 |
| VeliparibABT-888 | I–II | 1 | NCT01386385 |
| DBC-664 | I | 1 | NCT07705035 |
| Elzovantinib | I | 1 | NCT03993873 |
| NW-301V | I | 1 | NCT07875920 |
| PF-08046876 | I | 1 | NCT07090499 |
| TTX-080 | I | 1 | NCT04485013 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CarboplatinCarboplatine, Paraplatin | III | 9 | NCT04339218 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 6 | NCT04339218 |
| PemetrexedAxtle®, Pemfexy® | III | 6 | NCT04339218 |
| Bevacizumabavastin, MVASI | III | 4 | NCT07481786 |
| NivolumabOpdivo, ONO-4538 | II–III | 4 | NCT04929041 |
| IpilimumabYERVOY, ipililumab IV | II–III | 2 | NCT04929041 |
| LorlatinibLoratinib, Lorlatanib | III | 1 | NCT06858410 |
| CisplatinCis Platinum, Cisplatine | II | 4 | NCT04105270 |
| DurvalumabMEDI4736, Imfinzi® | II | 2 | NCT04105270 |
| AfatinibGilotrif®, Giotrif® | II | 1 | NCT05215548 |
| AvutometinibVS-6766 | II | 1 | NCT06495125 |
| Defactinib | II | 1 | NCT06495125 |
| DocetaxelTaxotere, Beizray® | II | 1 | NCT00334815 |
| EtoposideAvopef®, Etopophos Preservative Free® | II | 1 | NCT00334815 |
| FilgrastimRecombinant Human Granulocyte Colony-Stimulating Factor, Neupogen | II | 1 | NCT00334815 |
Sorted by most advanced phase and number of active trials. Showing 15 of 29 drugs.
All 50 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Acinar cell carcinoma 5 drugs
- Adenoid cystic carcinoma 26 drugs
- Adrenocortical carcinoma 28 drugs
- Pheochromocytoma 29 drugs
- Hemangiosarcoma 58 drugs
- Basal-cell carcinoma of the skin 28 drugs
- Cholangiocarcinoma 136 drugs
- Chordoma 11 drugs
- Desmoid Tumors 11 drugs
- Carcinoma, Endometrioid 13 drugs
- Bile duct neoplasm 36 drugs
- Extramammary Paget's disease 13 drugs
Broader categories
- Respiratory tract neoplasm 21 drugs
- Thoracic Neoplasms 25 drugs
- Carcinoma 137 drugs
- Glandular and epithelial neoplasm 12 drugs
- Adenocarcinoma 111 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D000077192 “Adenocarcinoma of Lung”.